Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK

References

• National Institute for Health and Clinical Excellence. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. London: National Institute for Clinical Excellence, 2002
   Google Scholar
• Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502-8
   PubMed Web of Science ®Google Scholar
• Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000;177:212-7
   PubMed Web of Science ®Google Scholar
• Taylor D, Paton K, Kerwin R. The South London & Maudsley NHS Trust & OXLEAS NHS Foundation Trust. 9th ed. London: Informa Healthcare, 2007
   Google Scholar
• Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-10
   PubMed Web of Science ®Google Scholar
• Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163(4):611-22
   PubMed Web of Science ®Google Scholar
• Chrzanowski WK, Marcus RN, Torbeyns A, et al. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189(2):259-66
   PubMed Web of Science ®Google Scholar
• Pigott TA, Carson WH, Saha AR, et al. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64(9):1048-56
   PubMed Web of Science ®Google Scholar
• Moeller KE, Shireman TI, Liskow BI. Relapse rates in patients with schizophrenia receiving aripiprazole in comparison with other atypical antipsychotics. J Clin Psychiatry 2006;67(12):1942-7
   PubMed Web of Science ®Google Scholar
• Haro JM, Salvador-Carulla L. The SOHO (Schizophrenia Outpatient Health Outcome) study: implications for the treatment of schizophrenia. CNS Drugs 2006;20(4):293-301
   PubMed Web of Science ®Google Scholar
• Reaney MD, Lees M, Wild D, et al. Using direct utility elicitation to assess the impact of schizophrenia and schizophrenia treatment-related adverse effects on quality of life: A patient study. J Psychopharmacology, 2006:20(5)Suppl TA17
   Google Scholar
• Ulcickas Yood M, deLorenze G, Quesenberry CPJ, et al. The incidence of diabetes in atypical antipsychotic users differs according to agent: results from a multisite epidemiologic study. International Society of Pharmacoepidemiology 2007; Toronto, Canada; 2007.
   Google Scholar
• Novartis Pharmaceuticals UK Ltd. Clozapine (Clozaril) Summary of Product Characteristics. Frimley, Surrey, 2005.
   Google Scholar
• Leibson CL, Burke JP, Ransom JE, et al. Relative risk of mortality associated with diabetes as a function of birth weight. Diabetes Care 2005;28(12):2839-43
   PubMed Web of Science ®Google Scholar
• Farahati F, Boucher M, Moulton K, et al. Atypical antipsychotic monotherapy for schizophrenia: clinical review and economic evaluation of first year of treatment [Technology report number 91]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007
   Google Scholar
• Thompson A, Shaw M, Harrison G, et al. Patterns of hospital admission for adult psychiatric illness in England: analysis of Hospital Episode Statistics data. Br J Psychiatry 2004;185:334-41
   PubMed Web of Science ®Google Scholar
• Curtis L, Netten A. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2006.
   Google Scholar
• UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998;317(7160):720-6.
   Google Scholar
• Hansen KA. Hyperprolactinemia and the Dopamine Receptor. US Endocrine Disease, 2006. Available at: http://www.touchbriefings.com/pdf/1815/hansenpdf (last accessed April 2008)
   Google Scholar
• Faulkner G, Cohn T, Remington G. Interventions to reduce weight gain in schizophrenia. Cochrane Database Syst Rev 2007;(1):005148
   Google Scholar
• British National Formulary 53. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2007.
   Google Scholar
• Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000;17(5):479-500
   PubMed Web of Science ®Google Scholar
• Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001;10(8):779-87
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London; 2004.
   Google Scholar
• Kane JM, Osuntoken O, Kryzhanovskaya LA, et al. A 28-week randomised, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia Presented at: 161st Annual Meeting of the American Psychiatric Association, Washington, DC, 2008.
   Google Scholar
• Kasper S, Winkler D. Addressing the limitations of the CATIE study. World J Biol Psychiatry 2006;7:126-7
   PubMed Web of Science ®Google Scholar
• Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-87
   PubMed Web of Science ®Google Scholar
• Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161(9):1709-11
   PubMed Web of Science ®Google Scholar
• Miller EA, Leslie DL, Rosenheck RA. Incidence of new-onset diabetes mellitus among patients receiving atypical neuroleptics in the treatment of mental illness: evidence from a privately insured population. J Nerv Ment Dis 2005;193(6):387-95
   PubMed Web of Science ®Google Scholar
• Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163(12):2080-9
   PubMed Web of Science ®Google Scholar
• Bagnall A, Jones L, Ginnelly L, et al. A rapid and systematic review of atypical antipsychotics in schizophrenia. York: NHS Centre for Reviews and Dissemination, 2001
   Google Scholar
• Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005;19(1):1-93
   PubMedGoogle Scholar
• ADA/APA/AACE/NAASO. Consensus development conference on antipsychotic drugs and obesity and diabetes. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Diabetes Care 2004;27(2):596-601.
   Google Scholar
• De Hert M, Hanssens L, van Winkel R, et al. Reversibility of Antipsychotic Treatment–Related Diabetes in Patients With Schizophrenia. Diabetes Care 2006;29:2329-30
   PubMed Web of Science ®Google Scholar
• De Hert M, Hanssens L, van Winkel R, et al. A Case Series: Evaluation of the Metabolic Safety of Aripiprazole. Schizophrenia Bull 2007;33(33):823-30
   PubMedGoogle Scholar